Home > Cardiology > ESC 2022 > Meta-analysis of DELIVER and EMPEROR-Preserved

Meta-analysis of DELIVER and EMPEROR-Preserved

Presented By
Dr Muthiah Vaduganathan, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Conference
ESC 2022
Trial
Phase 3, DELIVER, EMPEROR-Preserved
In a meta-analysis of SGLT2 inhibitors in heart failure patients with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), reduced risk of cardiovascular death and hospitalisation for heart failure was observed across patient subgroups, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction. Although there is strong evidence that SGLT2 inhibitors should be used to treat patients with heart failure with reduced ejection fraction (HFrEF), it is not yet well established what the benefits might be for individuals with higher ejection fractions. In the last year, 2 large randomised trials have reported the efficacy of SGLT2 inhibition in HFpEF/HFmrEF: DELIVER (NCT03619213) and EMPEROR-Preserved (NCT03057951). Dr Muthiah Vadu...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on